Home Companies Catalysts Deep Dives
Soliris eculizumab APPROVED
Drug Profile
ModalityAntibody
RouteIV
Therapy AreaRare Disease
Launch2007-03-16
US LOE2027-03-01
Peak Sales Est$1000M
Formulations[{"id":"soliris-iv","doses":"300mg","route":"IV","device":"IV infusion","setting":"CLINIC","frequenc
Companies
AZN (ORIGINATOR)100%
Mechanism: C5 inhibitor
Expert: Humanized monoclonal antibody that binds complement C5, preventing cleavage to C5a and C5b and inhibiting terminal complement-mediated hemolysis and inflammation.
Everyday: Blocks a protein in the immune system that mistakenly attacks the body's own red blood cells.
Targets: ["C5"]
Revenue History
PeriodRevenue ($M)
2023$1,842M
2024$1,523M
Q1 2025$340M
Programs (3)
IndicationStageKey StudyRegional Status
PNHAPPROVEDTRIUMPH[{"stage":"APPROVED","region":"US","approval_date":"2007-03-16"},{"stage":"APPRO
aHUSAPPROVEDC08-002/003[{"stage":"APPROVED","region":"US","approval_date":"2011-09-23"},{"stage":"APPRO
gMGAPPROVEDREGAIN[{"stage":"APPROVED","region":"US","approval_date":"2017-10-23"},{"stage":"APPRO
Notes
C5 inhibitor. Being replaced by Ultomiris.
Data from Supabase · Updated 2026-03-24